<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03430843</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-A317-302</org_study_id>
    <nct_id>NCT03430843</nct_id>
  </id_info>
  <brief_title>A Study of BGB-A317 Versus Chemotherapy as Second Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma</brief_title>
  <official_title>A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody BGB-A317 Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of BGB-A317 as second line
      treatment in patients with advanced unresectable/metastatic ESCC that has progressed during
      or after first line therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2018</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>approximately 2 years from date of first randomization</time_frame>
    <description>Length of time from study treatment initiation to death of any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>Clinical response rate of treatment (CR + PR) according to RECIST v1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>The interval from study treatment initiation until the determination of disease progression according to RECIST v1.1 criteria or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>2 years</time_frame>
    <description>The interval from the date of the first response (complete response or partial response) is achieved to the earlier of the first documentation of definitive disease progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Health-Related Quality of Life Questionnaire</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety will be analyzed through the incidence of adverse events.</measure>
    <time_frame>From the first dose date to 30 days after the last dose date</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety will be analyzed through the incidence of immune-related adverse events.</measure>
    <time_frame>From the first dose date to 90 days after the last dose date</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety will be analyzed through the incidence of serious adverse events.</measure>
    <time_frame>From the first dose date to 30 days after the last dose date</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety will be analyzed through the incidence of laboratory abnormalities.</measure>
    <time_frame>From the first dose date to 30 days after the last dose date</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma (ESCC)</condition>
  <arm_group>
    <arm_group_label>BGB-A317</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BGB-A317 will be administered with 200 mg intravenous dosing (IV) on Day1, given every 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigator chosen chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel will be administered at a dose of 135-175 mg /mÂ² IV, Day 1, given every 21 days or 80-100mg/m2 IV given on a weekly schedule.
OR docetaxel will be administered at a dose of 75 mg/m2 IV, Day 1, given 21 days.
OR irinotecan will be administered at a dose of 125mg/m2 IV, Day 1, 8, given 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-A317</intervention_name>
    <description>Anti-PD-1 ANTIBODY</description>
    <arm_group_label>BGB-A317</arm_group_label>
    <other_name>Tislelizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel, or Docetaxel, or Irinotecan</intervention_name>
    <description>One of the following three single-agent chemotherapies as determined by the Investigator Paclitaxel, or Docetaxel, or Irinotecan</description>
    <arm_group_label>Investigator chosen chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pathologically (histologically or cytologically) confirmed diagnosis of esophageal
             squamous cell carcinoma (ESCC)

          2. Tumor progression during or after first-line treatment for advanced unresectable /
             metastatic ESCC

          3. At least one measurable/evaluable lesion by RECIST v1.1

          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 prior to
             randomization

          5. Adequate End organ function

        Exclusion Criteria:

          1. Receipt of 2 or more prior systemic treatments for advanced/metastatic unresectable
             ESCC

          2. History of gastrointestinal perforation and /or fistula or aorto-esophageal fistula
             within 6 months prior to randomization

          3. Apparent tumor invasion into organs located adjacent to the esophageal disease site
             (eg, aorta or respiratory tract) at an increased risk of fistula in the study
             treatment assessed by investigator

          4. Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent
             drainage

          5. Received prior therapies targeting PD-1 or PD-L1

          6. Prior malignancy active within the previous 2 years (exceptions include the tumor
             under investigation in this trial, and locally recurring cancers that have undergone
             curative treatment, such as resected basal or squamous cell skin cancer, superficial
             bladder cancer or carcinoma in situ of the prostate, cervix or breast)

          7. Active brain or leptomeningeal metastasis.

          8. Has active autoimmune disease or history of autoimmune diseases at high risk for
             relapse

          9. Known history of, or any evidence of interstitial lung disease, non-infectious
             pneumonitis, pulmonary fibrosis diagnosed based on imaging or clinical findings, or
             uncontrolled systemic diseases, including diabetes, hypertension, acute lung diseases,
             etc

         10. Known history of Human Immunodeficiency Virus (HIV)

         11. Has cardiovascular risk factors

         12. Pregnant or breastfeeding woman.

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Virginia Paton, Senior Director</last_name>
    <phone>+15106974727</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Baohong Guo, Medical Director</last_name>
    <phone>+86 10 8514 8638</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical University</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2018</study_first_submitted>
  <study_first_submitted_qc>February 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2018</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Unresectable</keyword>
  <keyword>metastatic</keyword>
  <keyword>second-line</keyword>
  <keyword>squamous</keyword>
  <keyword>esophagus</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>docetaxel</keyword>
  <keyword>irinotecan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

